Roche México

What Roche México does

Roche M\u00e9xico is the Mexican subsidiary of F. Hoffmann-La Roche Ltd, a Swiss multinational pharmaceutical and diagnostics group founded in 1896, operating under the legal entity Productos Roche, S.A. de C.V. and headquartered at Cerrada de Bezares 9 in Mexico City. The company operates across three divisions: Farmac\u00e9utica (pharmaceuticals spanning oncology, hematology, neurosciences, pulmonology, rare diseases, and rheumatoid arthritis), Diagn\u00f3stica (diagnostics including centralized laboratory solutions, point-of-care testing, digital solutions under Roche Information Solutions/navify, and laboratory consulting), and Diabetes Care (Accu-Chek blood glucose monitoring). Core technologies include subcutaneous drug administration for cancer treatment (launched from 2022, reducing infusion times from hours to minutes), biomarker-driven precision medicine integrated with molecular diagnostics, decentralized point-of-care testing (PCR, clinical chemistry, coagulation, cardiac markers, glucose), and a digital health ecosystem connecting diagnostic infrastructure with medical insights.

The business model combines enterprise field sales targeting hospitals and medical specialists with a nationwide network of 12 authorized pharmaceutical distributors (Farmac\u00e9uticos Maypo, Nadro, Pharma Plus, Pharma Tycsa, and others), dedicated call centers for patient support (POR TI program, Accu-Chek), and the Tienda Roche Diagn\u00f3stica online channel. Roche M\u00e9xico has committed MX$1.2 billion (approximately US$60 million) to clinical research in Mexico for 2025-2026 across 16 new studies and approximately 1,200 additional patients, positioning the country as a regional clinical trial hub. The company employs between 1,001 and 5,000 people, maintains COFEPRIS regulatory registration (223300201B1069), runs the 42-year-old Premio Rosenkranz medical research award, and operates strategic partnerships including with the Union for International Cancer Control (UICC) and Instituto WifOR.

Name

Roche México

Legal name

Productos Roche, S.A. de C.V.

Website

https://roche.com.mx

Company type

Private

Founded year

1896

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Roche M\u00e9xico is the Mexican subsidiary of Swiss multinational F. Hoffmann-La Roche Ltd, delivering pharmaceutical therapies (oncology, hematology, rare diseases, neurosciences, rheumatology), diagnostic solutions, and Accu-Chek diabetes care to hospitals, laboratories, specialists, and patients across Mexico through enterprise sales and a 12-distributor network.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industries

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Gastroenterology Specialty Pharmaceuticals (HLAIACAE)

Keywords

• Pharmaceutical products
• Diagnostic solutions
• Oncology treatments
• Laboratory diagnostics
• Diabetes management

Headquarters

HQ city

Ciudad De León

HQ country

Mexico

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical Products: Roche México generates primary revenue through the sale of innovative pharmaceutical products including oncology medications (breast cancer, lung cancer, liver cancer), hematology treatments (hemophilia, chronic lymphocytic leukemia, lymphoma), neurosciences (multiple sclerosis), immunology (rheumatoid arthritis), and rare diseases. The pharmaceutical division integrates research from Roche, Genentech (US), and Chugai (Japan).
2. Diagnostic Solutions: Revenue from diagnostic tests, instruments, and digital solutions. Includes laboratory solutions, point-of-care testing, molecular diagnostics, and pathology services. Products span oncology, cardiometabolic conditions, infectious diseases, and women's health.
3. Diabetes Care (Accu-Chek): Blood glucose monitoring products and services through the Accu-Chek brand, including meters, test strips, and patient support through the call center.
4. Laboratory Consulting Services: Strategic consulting services to improve laboratory efficiency and productivity, including strategic design, technological innovation, patient experience optimization, and business strategy transformation.

Go-to-market motion3 records

Distribution channels6 records

Marketing channels6 records

Core offering

Roche México is the Mexican subsidiary of F. Hoffmann-La Roche Ltd, operating across three divisions: Farmacéutica (pharmaceutical solutions in oncology, hematology, neurosciences, pulmonology, rare diseases, and rheumatoid arthritis), Diagnóstica (diagnostic instruments, reagents, point-of-care testing, digital health solutions, and laboratory consulting), and Diabetes Care (Accu-Chek blood glucose monitoring). The company combines pharmaceutical research integrated with Genentech (US) and Chugai (Japan) with a comprehensive diagnostics portfolio to enable precision medicine across Mexico.

Product overview

Roche México operates as a pharmaceutical and diagnostics company organized into three main divisions: Farmacéutica (pharmaceutical solutions), Diagnóstica (diagnostic solutions), and Diabetes Care. The pharmaceutical division focuses on oncology (breast cancer, lung cancer, hepatocellular carcinoma), hematology (hemophilia, chronic lymphocytic leukemia, lymphoma), neurosciences (multiple sclerosis), pulmonology (cystic fibrosis, influenza), rare diseases, and rheumatoid arthritis. The diagnostics division provides laboratory solutions, point-of-care testing, digital health solutions under Roche Information Solutions, and strategic consulting services. The diabetes care division offers Accu-Chek monitoring systems. A patient engagement platform called 'Una Opción Para Ti' provides clinical trial information and disease resources.

Differentiator

Problem solved

Functional benefit

Brands

• Una Opción Para Ti: Patient resource platform for clinical trials and disease information
• Roche Diabetes Care
• Roche Information Solutions
• Roche Diagnóstica

Products and services

• Oncología (Oncology) Pharmaceutical solutions for cancer treatment including precision medicine, genomic sequencing, targeted therapies, and immunotherapy for breast cancer, lung cancer, hepatocellular carcinoma, and other tumor types.
• Hematología (Hematology) Blood disorder treatments including hemophilia, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma.
• Neurociencias (Neurosciences) Treatments for multiple sclerosis, the leading disabling non-accident disease in young adults, where immune cells attack nerve cells and connections in brain and spinal cord.
• Neumología (Pulmonology) Respiratory treatments including cystic fibrosis (chronic incurable disease causing thick mucus buildup) and influenza management.
• Enfermedades Raras (Rare Diseases) Treatments for rare diseases affecting approximately 8% of the global population, with an estimated 10 million people in Mexico living with a rare disease or low-prevalence condition.
• Artritis Reumatoide (Rheumatoid Arthritis) Treatment for chronic inflammatory autoimmune disease primarily affecting joints of hands, feet, and wrists, causing pain and disability; the disease is three times more common in women.
• Soluciones de Laboratorio (Laboratory Solutions) Clinical laboratory solutions including clinical chemistry, immunology, coagulation, hematology, urinalysis, blood safety, pathological anatomy, and molecular laboratory services with fully automated IHQ and HIS staining.
• Point of Care Decentralized diagnostic solutions enabling testing at patient point of contact, including PCR, clinical chemistry, blood gases, electrolytes, coagulation, urinalysis, cardiac markers, glucose, lipid profiles, and rapid COVID tests.
• Soluciones Digitales (Digital Solutions) Digital ecosystem solutions for healthcare connecting digital infrastructure, operational excellence, and medical insights for precise diagnostics under Roche Information Solutions, including the navify platform.
• Consultoría (Consulting) Strategic consulting services for laboratory efficiency and productivity, including strategic design, technological innovation, patient experience optimization, and business strategy transformation, delivered by 350+ consultants worldwide.
• Diabetes Care - Accu-Chek Diabetes monitoring and management solutions through the Accu-Chek system, including meters, test strips, and patient support via a dedicated customer support center.

Quantifiable outcome

• MX$1.2 billion (US$60 million) clinical research investment for 2025-2026 including 16 new studies and 1,200 additional patients
• +3 more outcomes

Named customers4 records

Segments7 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and flagship.

• Instituto WifOR (WifOR Institute)coreStrategic or Co-development PartnerResearch partnership to measure the socioeconomic burden of chronic diseases in Latin America. Roche has invested in this alliance to quantify the value that medical innovations bring to society, analyzing the impact of treatments for HER2+ breast cancer, diabetic macular edema, age-related macular degeneration, and multiple sclerosis. The study demonstrates that investment in health drives economic growth.
• Union for International Cancer Control (UICC)flagshipStrategic or Co-development PartnerStrategic partner supporting the 'United by Unique' campaign for World Cancer Day 2025-2027, advancing more equitable, people-centered cancer care. The partnership focuses on rethinking how cancer research, care design, and treatment are approached from a collaborative global perspective with local impact.
• Healthcare Institutions and Research CenterscoreStrategic or Co-development PartnerRoche conducts clinical trials in partnership with hospitals and research centers throughout Mexico. For 2025-2026, 16 new clinical studies are planned with approximately 1,200 additional patients, positioning Mexico as a potential regional research hub for clinical trials.
• Authorized Distributors (12 distributors)coreChannel Partner/ Reseller/ DistributorNetwork of 12 authorized pharmaceutical distributors including Farmacéuticos Maypo, Nadro, Pharma Plus, Pharma Tycsa, Fármacos Nacionales, Fármacos Especializados, and others enabling comprehensive product distribution across Mexico.
• Mexican Health Authorities (COFEPRIS)coreOthersCollaboration with COFEPRIS for regulatory approvals, pharmacovigilance reporting, and compliance with Mexican pharmaceutical regulations. Roche maintains COFEPRIS registration for its products.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Market position

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/RocheMexico
• LinkedInlinkedin.com/company/rochemexico
• Instagraminstagram.com/roche_latam/?hl=es
• Xx.com/rochemexico

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Roche México